Docon Technologies updates Thyrocare share pledge status

Docon Technologies Private Limited, a promoter of Thyrocare Technologies Limited, announced on November 11, 2025, an update regarding the pledge on 32,323,232 shares of Thyrocare, representing 60.93% of its total share capital. This encumbrance was initially created in favor of Catalyst Trusteeship Limited as Debenture Trustee for Non-Convertible Debentures (NCDs) issued by API Holdings Limited, Docon’s holding company.

API Holdings Limited has fully repaid and redeemed its Series 2 NCDs, amounting to ₹500 crore, on October 28, 2025. However, Docon clarified there is no change in the number of encumbered shares of Thyrocare. The updated details reflect the current position of promoter shareholding and debenture series.

The shares remain pledged for 12,000 unlisted, unrated, secured, redeemable non-convertible debentures with a face value of INR 10,00,000 issued by API.